Finch Announces Reverse Stock Split of Common Stock
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
Finch Therapeutics Announces Executive Leadership Transitions
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
